SCHEMBL23749755

SCHEMBL23749755

CC(C)(C)OC(=O)Nc1cc(-n2ccsc2=N)ccn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 1/20 0.40
▸ GSK3B P49841 1/20 0.38
▸ DYRK1A Q13627 1/20 0.38
▸ METAP1 P53582 1/20 0.38
▸ ATR Q13535 1/20 0.37
▸ IRAK4 Q9NWZ3 1/20 0.36
▸ TGFBR1 P36897 1/20 0.35
▸ P2RX3 P56373 1/20 0.35
▸ SCN9A Q15858 1/20 0.35
▸ SREBF2 Q12772 1/20 0.35
▸ PIK3C3 Q8NEB9 1/20 0.34
▸ DGAT1 O75907 1/20 0.34
▸ NPC1 O15118 2/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ PKM P14618 1/20 0.33
▸ AAK1 Q2M2I8 2/20 0.33
▸ TP53 P04637 1/20 0.33
▸ CCR2 P41597 1/20 0.33
▸ BRD4 O60885 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23727741 0.83 IGF1R (0.38) IGF1RGSK3BDYRK1AMETAP1ATR
SCHEMBL23727744 0.83 IGF1R (0.38) IGF1RGSK3BDYRK1AMETAP1ATR
SCHEMBL23727896 0.82 PIK3C3 (0.38) PIK3C3NPC1RAB9ASMN1; SMN2PKM
SCHEMBL23749931 0.79 IGF1R (0.37) IGF1RGSK3BDYRK1AMETAP1ATR
SCHEMBL30130815 0.73 GLS (0.45) BRD4
SCHEMBL23749868 0.73 GLS (0.45) BRD4
SCHEMBL28848819 0.72 PIK3C3 (0.39) IGF1RGSK3BDYRK1AATRIRAK4
SCHEMBL25776011 0.71 PRKDC (0.47) GSK3BDYRK1APIK3C3BRD4
SCHEMBL828560 0.71 TP53 (0.51) NPC1RAB9ASMN1; SMN2PKMTP53
SCHEMBL1192656 0.71 ATR (0.50) IGF1RGSK3BDYRK1AMETAP1ATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617785-B2 Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss THE ROCKEFELLER UNIVERSITY (US) 2026-05-05 — — US disclosed
EP-4100008-B1 PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS UNIV ROCKEFELLER (US) 2025-04-02 — — EP disclosed
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2023-05-04 — — US disclosed
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2023-05-04 — — US disclosed
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2023-05-04 — — US disclosed
EP-4100008-A1 PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS The Rockefeller University (US) 2022-12-14 — — EP disclosed
WO-2021158936-A1 PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2021-08-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12617785-B2 Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss YAP1, LATS2, LATS1 IGF1R 2824/4885GSK3B 606/4885DYRK1A 833/4885
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS LATS2, LATS1, YAP1 IGF1R 3927/4885GSK3B 516/4885DYRK1A 400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback